Citi lifts Elior Group price target to EUR 4.00, maintains buy

Published 27/05/2025, 08:04
Citi lifts Elior Group price target to EUR 4.00, maintains buy

On Tuesday, Citi analysts, led by Leo Carrington, increased the price target for Elior Group SA (EPA:ELIOR:FP) shares to EUR 4.00, up from EUR 3.80, while sustaining a Buy rating on the stock. The adjustment comes amid a backdrop of financial performance that has seen Elior’s revenue growth projections for FY25 tempered by a robust improvement in first-half operating margins.

Elior’s smaller scale in the contract catering market, relative to its peers, introduces a level of unpredictability due to the impact of significant country-specific issues, such as those in Italy, and the timing of contract commencements. Nonetheless, Citi analysts expressed confidence in the company’s growth potential, citing an expected acceleration in the second half of the year. This anticipation is supported by contracts that have been signed but not yet started, which are projected to increase growth to 2.0% in the second half from 1.5% in the first half.

The first-half gross wins on a signed basis amounted to approximately 9.0% gross contract growth, which surpasses the 7.1% recorded in the profit and loss statement. Citi’s forecast for Elior includes an 18% adjusted EBIT compound annual growth rate (CAGR) from 2024 to 2027. Given this forecast and the current valuation, which analysts consider modest compared to the company’s historical performance, Citi continues to recommend Elior Group as an attractive investment, albeit with a high-risk classification.

Citi’s commentary underscores the belief that despite the operational volatility, the underlying signed contracts are a strong indicator of future growth. This sentiment is buoyed by the company’s financials, which suggest a promising trajectory for the adjusted EBIT CAGR over the next few years. Elior’s stock continues to hold appeal for Citi, with the revised price target reflecting an optimistic outlook for the company’s financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.